Revance Reports Second Quarter 2020 Financial Results, Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Revance Therapeutics (RVNC) Misses Q2 EPS by 11c
August 6, 2020 5:20 PM EDTRevance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($1.12), $0.11 worse than the analyst estimate of ($1.01). Revenue for the quarter came in at $299 thousand versus the consensus estimate of $410 thousand.
2020 Financial Outlook
We are developing our acquisition accounting for HintMD and once completed we can provide GAAP... More
